echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Heavy! After the Ice Bucket Challenge, then lift the craze, smile pass waiting for you to relay!

    Heavy! After the Ice Bucket Challenge, then lift the craze, smile pass waiting for you to relay!

    • Last Update: 2020-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    There is a disease that can't be cured. It will make the expression stiff, the smile will gradually lose, and even make the lung as hard as leather. Breathing becomes a luxury.as the disease progresses, they may not be able to show their face any more one day.this is scleroderma, which takes away smiles and threatens lives.since the world smile day was launched, people, patients, doctors and other people from all walks of life have passed on their smiles by sharing smiling posters on social media, appealing to the community to pay attention to scleroderma.the activity plans to collect 629 smiling posters on world scleroderma day on June 29. So far, 7598 posters have been shared on social media (circle of friends, microblog, etc.). In addition, the topic of "smile delivery plan" has attracted 2.1 million people's attention on microblog.scan the QR code below the poster and participate in the smile relay! (in the poster, Zheng AI, founder of scleroderma care home and scleroderma patient) Zheng AI, founder of scleroderma care home and scleroderma patient, introduced: "scleroderma will not only cause abnormal appearance of patients, but also seriously affect the quality of life and even cause death.anyone has the possibility of disease. However, because scleroderma is rare, people do not understand and pay enough attention to it. Many catastrophic losses occur in the families of patients.we hope to call on more people to understand scleroderma, care for scleroderma patients, and let the smile bloom on their faces."about one third of scleroderma patients die of interstitial lung disease (SSC ILD). Systemic sclerosis, also known as scleroderma, is a rare autoimmune disease that affects connective tissue and cannot be cured.because scleroderma affects connective tissue, symptoms can occur in any area of the body, including skin, muscles, blood vessels and internal organs, making it difficult to diagnose. The incidence rate ofis about 10/100000, and most of them are female patients.the most obvious appearance features of scleroderma are thickening and hardening of the whole body skin, loss of original elasticity, disappearance of normal facial wrinkles, narrowing of nasal wings and thinning of lips, forming a "mask face".up to 90% of patients with systemic sclerosis may have different degrees of interstitial lung disease. 2. About 25% of scleroderma patients have significant lung involvement within 3 years after diagnosis.▲(In the poster, Professor Zeng Xiaofeng, director of Rheumatology and Immunology Department of Peking Union Medical College Hospital, President of Rheumatology branch of Chinese Medical Association, former member of Rheumatology branch of Chinese Medical Association and director of Rheumatology and Immunology Department of Peking Union Medical College Hospital, stressed: "pulmonary fibrosis caused by scleroderma is called scleroderma related interstitial lung disease (SSC ILD), which is a common table of scleroderma Now, it is also the leading cause of death.pulmonary lesions make it difficult for patients to breathe, chest tightness, shortness of breath, and decreased lung function.because SSC ILD is a progressive lung disease, many patients may not have obvious symptoms in the early stage, but if they are not diagnosed and intervened in time, the prognosis is poor."the diagnosis is difficult and the treatment is late. Anti fibrosis drugs will bring new choices. It is difficult to diagnose SSC ILD and treat late body. On the one hand, if the patient takes pulmonary fibrosis as the first symptom, the probability of misdiagnosis will be greatly increased, because the symptoms are similar to the pathological types and imaging features of idiopathic pulmonary fibrosis (IPF), if the skin or other organs of patients with scleroderma are suffering from scleroderma Without sclerosis, it is difficult for doctors to distinguish it as scleroderma related interstitial lung disease (SSC ILD); on the other hand, when patients have multiple systemic sclerosis symptoms and doctors realize that SSC ILD changes, it is often too late, and the treatment is very limited.therefore, Professor Zeng Xiaofeng stressed: "it is very important for patients with scleroderma to monitor their lung function regularly. If there is lung disease, they can be found and treated as soon as possible, so as to delay the deterioration of the disease.high resolution CT (HRCT) is the most important means of clinical detection of lung lesions, with the advantages of simple, easy and non-invasive.B ultrasound and lung biopsy are also important measures to help diagnosis."in clinical practice, there is no drug with definite curative effect, and this state has not changed until recent years.vegate was approved for marketing in China in 2017, and the first approved indication was idiopathic pulmonary fibrosis (IPF).in addition, in September last year, SSC ILD, the second indication for vegat, was approved in the United States based on the confirmed clinical data of senscis.senscis is a phase III, double-blind, randomized, placebo-controlled trial involving 576 SSC ILD patients (including Chinese patients) from 32 countries and regions.the primary end point was the annual decrease rate of forced vital capacity (FVC) (ml / year) during 52 weeks.results showed that compared with placebo, nidanib could slow down the decline of lung function in patients with SSc ILD.among patients treated with nidanib, the annual decline rate of FVC was relatively reduced by about 44% 4.in China, SSC ILD has been listed in the list of rare diseases, and there is a great demand for unsatisfied treatment in clinic.it is reported that the SSC ILD indication of Viagra (nidanib) has been submitted for listing in China in June last year, and has been included in the rapid review channel. It is expected that this indication will be approved as soon as possible in China, so that more patients can get out of the dilemma of no medicine and bring more benefits to SSc patients in China.scan the QR code under the poster and keep smiling! Smile to the sun, embrace, hope we believe that the smile can last for how long, the theme of life can last, let us join the ranks of passing smile, let more scleroderma patients can breathe smoothly, smile forever! 1 Cottin V, et al. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir. Res. 2019;20(1):13.2 Silver, et al. Management of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD). Rheum Dis Clin North Am. 2015. 41 (3): 439–457.3 Denton CP, Khanna D. Systemic sclerosis.Published 13 April,2017 Last accessed March 2019.4Flaherty K, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases N Eng J Med. Published 29 September, two thousand and nineteen NEJM.org . doi: 10.1056/nejmoa1908681 edited by: Li Hui reviewed by: Wang Lina contribution to medical journal Public email: yishibao2017@163.com [note] some of the pictures are from the network and wechat circle of friends. Dear Author, the doctor's Daily has prepared the contribution fee for you. Please contact the editor on duty at 58302828-6808 for past review A kind of What is the child thinking when you smoke? This eight minute video tells you A kind of Hospital headlines | women love to eat barbecue "five cooked" and suffer from rare hepatic echinococcosis A kind of Zhao Jiajun, President of Shandong Provincial Hospital A kind of The live broadcasting room of "doctor's Daily" is heavily attacked, with 60 live broadcasts and more than 8 million people participating. There is no distance between the authority and you! A kind of Share your 15 years of medical experience A kind of Reading is a kind of power when the latest 645 issue of "doctor's Daily" is released A kind of Self directed and self performed micro film by doctor newspaper! A kind of [Video] 2019 doctor's Daily: pay homage to life and doctors A kind of [Video] 2018 doctor's Daily: creating a butterfly for your dream! Look for someone else! Looking for professional and dedicated person! Look for diligent and responsible people! West 2nd Ring Road, Beijing New Shijing office, waiting for you! New media operation director 1 senior medical editor 5 fusion media reporters resume please send to: yishibao2017@163.com At present, 1130000 + doctors have paid attention to join us
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.